Deliver Your News to the World

U.S. Department of Health and Human Services Completes Funding of 2006 Contract Award to CSC´s DVC and Baxter


Computer Sciences Corporation (NYSE: CSC) today announced that DynPort Vaccine Company LLC (DVC), a CSC company, in conjunction with Baxter International Inc. (NYSE: BAX), has received a $201.2 million contract modification from the U.S. Department of Health and Human Services (HHS) for the development of Baxter’s cell-cultured seasonal and pandemic influenza candidate vaccines. CSC reported the full potential contract value of $242.5 million in its initial press release announcing the HHS Office of Public Health Emergency Preparedness contract on May 4, 2006.

The contract funds development of the seasonal influenza vaccine through U.S. Food and Drug Administration (FDA) licensure, and the pandemic vaccine candidate through Phase 2 clinical trials in adults and pediatric Phase 1 clinical trials. DVC, the prime contractor for this effort, is providing overall management of the clinical trials. Baxter is developing the candidate vaccines, and will manufacture the vaccines and own all clinical data and licenses.

The clinical portion of a Phase 1/2 clinical trial to test the safety and immunogenicity of Baxter’s cell-culture-derived split virus seasonal influenza vaccine candidate in Europe was recently completed. Preliminary data announced in July 2007 indicate that the vaccine induced strong antibody responses and good tolerability in all study populations. DVC and Baxter vaccinated the first volunteers of a Phase 3 trial in healthy adults using the seasonal vaccine candidate in the U.S. on Nov. 26, and plan to enroll patients in a Phase 1 clinical trial for a pandemic influenza clade 2 strain vaccine candidate in 2008. This trial will also be conducted in the U.S.

“The progress made on the pandemic and seasonal influenza programs in such a short time reflects the priority and importance of this development program for both companies,” said Dr. Robert V. House, president and chief scientific officer of DVC. “By combining Baxter’s technology with DVC’s biologics life-cycle and contract management expertise, the team has made great progress in advancing these two influenza vaccine candidates.”

“The funding validates the potential for these cell culture vaccine candidates,” said Kim Bush, president of Baxter’s Vaccines business. “We look forward to continuing to develop influenza vaccines that may make a meaningful scientific and medical contribution to those using the vaccines and for government pandemic planning.”

About Baxter

Baxter International Inc., through its subsidiaries, assists health-care professionals and their patients with the treatment of complex medical conditions, including cancer, hemophilia, immune disorders, kidney disease and trauma. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients’ lives.

About DVC

DVC provides end-to-end program management and solutions for the development of biopharmaceutical products. For more information, visit DVC’s Web site at

DVC is part of CSC’s North American Public Sector business unit’s Government Health Services Division. CSC’s expertise in providing health services to government agencies has grown over the last five decades to offer commercial best practices integrated to meet federal, state and local healthcare requirements. Services range from optimizing claims processing and clinical information systems to operating disease surveillance systems and from developing vaccines to building the prototype for the Nationwide Health Information Network.

About CSC

Computer Sciences Corporation is a leading global IT services company. CSC’s mission is to provide customers in industry and government with solutions crafted to meet their specific challenges and enable them to profit from the advanced use of technology.

With approximately 87,000 employees, CSC provides innovative solutions for customers around the world by applying leading technologies and CSC’s own advanced capabilities. These include systems design and integration; IT and business process outsourcing; applications software development; Web and application hosting; and management consulting. Headquartered in El Segundo, Calif., CSC reported revenue of $14.9 billion for the 12 months ended March 30, 2007. For more information, visit the company’s Web site at

The safety and efficacy of these products in humans has not been established. These products are currently under clinical investigation and have not been licensed by the FDA.

This project has been funded in whole or in part with Federal (United States Government) funds from the Office of Public Health and Emergency Preparedness, Office of Research and Development Coordination, under contract number HHS0100200600013C. Pursuant to section 507 of P.L. 104-208 and Section 508 of P.L. 105-78, 100% of the total of this project’s costs are financed with Federal funds. The content of this publication does not necessarily reflect the views or policies of the United States Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

For More Information

Media Contacts

Christopher Bona, Baxter, (847) 948-2815

Bill Lackey, CSC, (310) 615-1700

April Finnen, DVC, (301) 607-5004

Investor Contacts:

Mary Kay Ladone, (847) 948-3371

Clare Trachtman, (847) 948-3085


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.